Kyle Harrison
concept

GLP-1

GLP-1

One-line definition: The class of weight-loss / diabetes drugs (Wegovy, Ozempic, compounded semaglutide) whose insatiable US demand is the actual fuel behind the MEDVI story.

How sources describe it

  • A precondition independent of AI: GLP-1 demand had to be “absolutely insatiable” — and it is. People want it now and don’t want to sit in a doctor’s office. (source: The $1B Rorschach Test - Research)
  • “Offering GLP-1s via Telehealth is such a gangbusters business you literally can’t NOT make money doing it.” (source: The $1B Rorschach Test - Research)
  • The FDA has been cracking down on grey-market / Chinese GLP-1s; legitimate players like Hims & Hers bought compounding pharmacies + a peptide facility ahead of it, raising the sustainability question for pure marketing layers. (source: The $1B Rorschach Test - Research)

Where it shows up

  • The $1B Rorschach Test - Research — the demand wave the essay says was actually being ridden.

Referenced in